AG-690/11026014, a novel PARP-1 inhibitor, protects cardiomyocytes from AngII-induced hypertrophy

Molecular and Cellular Endocrinology

Volumn 392, Issue 1-2, 2014, Pages 14-22

  Liu, Min ^a   Li, Zhe ^a   Chen, Guo Wen ^a   Li, Zhuo Ming ^a   Wang, Lu Ping ^a   Ye, Jian Tao ^a   Luo, Hai Bin ^a   Liu, Pei Qing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

6014; Cardiac hypertrophy; NAD; PARP 1; SIRT6

Indexed keywords

AG 690 11026014; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SIRTUIN 6; UNCLASSIFIED DRUG; AG-690; ANGIOTENSIN II; CARDIOTONIC AGENT; CYBB PROTEIN, RAT; MEMBRANE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NOX4 PROTEIN, RAT; REACTIVE OXYGEN METABOLITE; RECOMBINANT PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SIRTUIN; SIRTUIN 6, RAT; THIOGLYCOLIC ACID DERIVATIVE; XANTHINE DERIVATIVE;

ANIMAL CELL; ARTICLE; BIOASSAY; CELL CULTURE; CELL SURFACE; COMPUTER PROGRAM; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; MOLECULAR DOCKING; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOMEGALY; CELL PROTECTION; CHEMISTRY; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; HUMAN; IC50; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; UPREGULATION;

ANGIOTENSIN II; ANIMALS; CARDIOMEGALY; CARDIOTONIC AGENTS; CYTOPROTECTION; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MEMBRANE GLYCOPROTEINS; MOLECULAR DOCKING SIMULATION; MYOCYTES, CARDIAC; NAD; NADPH OXIDASE; POLY(ADP-RIBOSE) POLYMERASES; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECOMBINANT PROTEINS; SIRTUINS; THIOGLYCOLATES; UP-REGULATION; XANTHINES;

EID: 84901649931     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2014.05.010     Document Type: Article

References (34)

1. Alcendor R.R., Gao S., Zhai P., Zablocki D., Holle E., Yu X., Tian B., Wagner T., Vatner S.F., Sadoshima J. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ. Res. 2007, 100:1512-1521.
2. Ame J.C., Spenlehauer C., de Murcia G. The PARP superfamily. Bioessays 2004, 26:882-893.
3. Bartha E., Kiss G.N., Kalman E., Kulcsar G., Kalai T., Hideg K., Habon T., Sumegi B., Toth K., Halmosi R. Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure. J. Cardiovasc. Pharmacol. 2008, 52:253-261.
4. Cai Y., Yu S.S., Chen S.R., Pi R.B., Gao S., Li H., Ye J.T., Liu P.Q. Nmnat2 protects cardiomyocytes from hypertrophy via activation of SIRT6. FEBS Lett. 2012, 586:866-874.
5. Decker P., Miranda E.A., de Murcia G., Muller S. An improved nonisotopic test to screen a large series of new inhibitor molecules of poly(ADP-ribose) polymerase activity for therapeutic applications. Clin. Cancer Res. 1999, 5:1169-1172.
6. Gao J., Yang G., Pi R., Li R., Wang P., Zhang H., Le K., Chen S., Liu P. Tanshinone IIA protects neonatal rat cardiomyocytes from adriamycin-induced apoptosis. Trans. Res. 2008, 151:79-87.
7. Geistrikh I., Visochek L., Klein R., Miller L., Mittelman L., Shainberg A., Cohen-Armon M. Ca2+-induced PARP-1 activation and ANF expression are coupled events in cardiomyocytes. Biochem. J. 2011, 438:337-347.
8. Geng B., Cai Y., Gao S., Lu J., Zhang L., Zou J., Liu M., Yu S., Ye J., Liu P. PARP-2 knockdown protects cardiomyocytes from hypertrophy via activation of SIRT1. Biochem. Biophys. Res. Commun. 2013, 430:944-950.
9. Haigis M.C., Sinclair D.A. Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 2010, 5:253-295.
10. Jagtap P., Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov. 2005, 4:421-440.
11. Jain A.N. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J. Med. Chem. 2003, 46:499-511.
12. Javle M., Curtin N.J. The role of PARP in DNA repair and its therapeutic exploitation. Br. J. Cancer. 2011, 105:1114-1122.
13. Kulkarni S.S., Singh S., Shah J.R., Low W.K., Talele T.T. Synthesis and SAR optimization of quinazolin-4(3H)-ones as poly(ADP-ribose)polymerase-1 inhibitors. Eur. J. Med. Chem. 2012, 50:264-273.
14. Le K., Li R., Xu S., Wu X., Huang H., Bao Y., Cai Y., Lan T., Moss J., Li C., Zou J., Shen X., Liu P. PPARalpha activation inhibits endothelin-1-induced cardiomyocyte hypertrophy by prevention of NFATc4 binding to GATA-4. Arch. Biochem. Biophys. 2012, 518:71-78.
15. Luo X., Kraus W.L. On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev. 2012, 26:417-432.
16. Maejima Y., Kuroda J., Matsushima S., Ago T., Sadoshima J. Regulation of myocardial growth and death by NADPH oxidase. J. Mol. Cell Cardiol. 2011, 50:408-416.
17. Oh K.S., Lee S., Yi K.Y., Seo H.W., Koo H.N., Lee B.H. A novel and orally active poly(ADP-ribose) polymerase inhibitor, KR-33889 [2-[methoxycarbonyl(4-methoxyphenyl) methylsulfanyl]-1H-benzimidazole-4-carboxylic acid amide], attenuates injury in in vitro model of cell death and in vivo model of cardiac ischemia. J. Pharmacol. Exp. Ther. 2009, 328:10-18.
18. Pacher P., Szabo C. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc. Drug Rev. 2007, 25:235-260.
19. Peralta-Leal A., Rodriguez-Vargas J.M., Aguilar-Quesada R., Rodriguez M.I., Linares J.L., de Almodovar M.R., Oliver F.J. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Free Radic. Biol. Med. 2009, 47:13-26.
20. Pillai J.B., Russell H.M., Raman J., Jeevanandam V., Gupta M.P. Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure. Am. J. Physiol. Heart Circ. Physiol. 2005, 288:H486-96.
21. Pillai J.B., Isbatan A., Imai S., Gupta M.P. Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity. J. Biol. Chem. 2005, 280:43121-43130.
22. Pillai J.B., Gupta M., Rajamohan S.B., Lang R., Raman J., Gupta M.P. Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H1545-1553.
23. Pillai V.B., Sundaresan N.R., Kim G., Gupta M., Rajamohan S.B., Pillai J.B., Samant S., Ravindra P.V., Isbatan A., Gupta M.P. Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. J. Biol. Chem. 2010, 285:3133-3144.
24. Putt K.S., Hergenrother P.J. An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors. Anal. Biochem. 2004, 326:78-86.
25. Ruf A., de Murcia G., Schulz G.E. Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry 1998, 37:3893-3900.
26. Szabo C. Cardioprotective effects of poly(ADP-ribose) polymerase inhibition. Pharmacol. Res. 2005, 52:34-43.
27. Tao M., Park C.H., Bihovsky R., Wells G.J., Husten J., Ator M.A., Hudkins R.L. Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg. Med. Chem. Lett. 2006, 16:938-942.
28. Venkatachalam C.M., Jiang X., Oldfield T., Waldman M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J. Mol. Graph. Model. 2003, 21:289-307.
29. Vilar S., Cozza G., Moro S. Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. Curr. Top Med. Chem. 2008, 8:1555-1572.
30. Wang H.X., Yang H., Han Q.Y., Li N., Jiang X., Tian C., Du J., Li H.H. NADPH oxidases mediate a cellular "memory" of angiotensin II stress in hypertensive cardiac hypertrophy. Free Radic. Biol. Med. 2013, 65:897-907.
31. Wollert K.C., Drexler H. The renin-angiotensin system and experimental heart failure. Cardiovasc. Res. 1999, 43:838-849.
32. Wu G., Robertson D.H., Brooks C.L., Vieth M. Detailed analysis of grid-based molecular docking: A case study of CDOCKER-A CHARMm-based MD docking algorithm. J. Comput. Chem. 2003, 24:1549-1562.
33. Yu S.S., Cai Y., Ye J.T., Pi R.B., Chen S.R., Liu P.Q., Shen X.Y., Ji Y. Sirtuin 6 protects cardiomyocytes from hypertrophy in vitro via inhibition of NF-kappaB-dependent transcriptional activity. Br. J. Pharmacol. 2013, 168:117-128.
34. Zhang Y., Tocchetti C.G., Krieg T., Moens A.L. Oxidative and nitrosative stress in the maintenance of myocardial function. Free Radic. Biol. Med. 2012, 53:1531-1540.